Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients.
Lucchetta, Rosa Camila; Riveros, Bruno Salgado; Pontarolo, Roberto; Radominski, Rosana Bento; Otuki, Michel Fleith; Fernandez-Llimos, Fernando; Correr, Cassyano Januário.
Clinics (Sao Paulo)
; 72(5): 317-324, 2017 May.
Artigo em Inglês | MEDLINE | ID: mdl-28591345
Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients
A comparative study of five centrally acting drugs on the pharmacological treatment of obesity.
Diethylpropion and mazindol: An end to the discussion?
The efficacy of the appetite suppressant, diethylpropion, is dependent on both when it is given (day vs. night) and under conditions of high fat dietary restriction.
Six-month efficacy and safety of amfepramone in obese Mexican patients: a double-blinded, randomized, controlled trial.
A comparison of mazindol (Teronac) with diethylpropion in the treatment of exogenous obesity.
Binding of mazindol and analogs to the human serotonin and dopamine transporters.
Re-evaluation of the metabolism and excretion of diethylpropion in non-sustained and sustained release formulations.
Anorectic efficacy and safety of the diethylpropion-topiramate combination in rats.
D1 and D2 antagonists reverse the effects of appetite suppressants on weight loss, food intake, locomotion, and rebalance spiking inhibition in the rat NAc shell.